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VIEW AND REVIEW
A diagnostic approach for neurodegeneration 
with brain iron accumulation: clinical features, 
genetics and brain imaging 
Uma orientação diagnóstica para neurodegeneração com acúmulo cerebral de ferro: 
aspectos clínicos, genéticos e de neuroimagem
Rubens Paulo Araújo Salomão1, José Luiz Pedroso1, Maria Thereza Drumond Gama1, Lívia Almeida Dutra1, 
Ricardo Horta Maciel2, Clécio Godeiro-Junior3, Hsin Fen Chien4, Hélio A. G. Teive5, Francisco Cardoso2, 
Orlando G. P. Barsottini1
Neurodegeneration with brain iron accumulation (NBIA) 
represents a heterogeneous group of inherited neurodegenera-
tive diseases, characterized by excess iron accumulation, partic-
ularly in the basal ganglia, and to a lesser degree in substantia 
nigra and adjacent areas1. NBIA is considered to be a very rare dis-
ease group, with a prevalence of less than 1/1,000,000 in general 
population1. Common clinical features of NBIA include move-
ment disorders, particularly parkinsonism and dystonia, cogni-
tive dysfunction, pyramidal signs, and retinal abnormalities1,2,3.
Hunt in 1917 described a case report of juvenile parkinsonism 
associated with progressive atrophy of globus pallidus4. In 1922, 
Hallervorden and Spatz reported a family with five affected sisters 
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AbstrACt
Neurodegeneration with brain iron accumulation (NBIA) represents a heterogeneous and complex group of inherited neurodegenerative 
diseases, characterized by excessive iron accumulation, particularly in the basal ganglia. Common clinical features of NBIA include movement 
disorders, particularly parkinsonism and dystonia, cognitive dysfunction, pyramidal signs, and retinal abnormalities. The forms of NBIA 
described to date include pantothenase kinase-associated neurodegeneration (PKAN), phospholipase A2 associated neurodegeneration 
(PLAN), neuroferritinopathy, aceruloplasminemia, beta-propeller protein-associated neurodegeneration (BPAN), Kufor-Rakeb syndrome, 
mitochondrial membrane protein-associated neurodegeneration (MPAN), fatty acid hydroxylase-associated neurodegeneration (FAHN), 
coenzyme A synthase protein-associated neurodegeneration (CoPAN) and Woodhouse-Sakati syndrome. This review is a diagnostic 
approach for NBIA cases, from clinical features and brain imaging findings to the genetic etiology.   
Keywords: neurodegeneration with brain iron accumulation; NBIA; clinical features; brain imaging; genetics. 
resumo
A neurodegeneração com acúmulo cerebral de ferro (sigla em inglês NBIA) representa um grupo heterogêneo e complexo de doenças 
neurodegenerativas hereditárias, caracterizada pelo acúmulo cerebral de ferro, especialmente nos núcleos da base. O quadro clínico das NBIAs 
em geral inclui distúrbios do movimento, particularmente parkinsonismo e distonia, disfunção cognitiva, sinais piramidais e anormalidades da 
retina. As formas de NBIA descritas até o momento incluem neurodegeneração associada a pantothenase kinase (PKAN), neurodegeneração 
associada a phospholipase A2 (PLAN), neuroferritinopatia, aceruloplasminemia, neurodegeneração associada a beta-propeller protein (BPAN), 
síndrome de Kufor-Rakeb, neurodegeneração associada a mitochondrial membrane protein (MPAN), neurodegeneração associada a “fatty acid 
hydroxylase” (FAHN), neurodegeneração associada a coenzyme A synthase protein (CoPAN) e síndrome de Woodhouse-Sakati. Esta revisão é uma 
orientação para o diagnóstico das NBIAs, partindo das características clínicas e achados de neuroimagem, até a etiologia genética.
Palavras-chave: Neurodegeneração com acúmulo cerebral de ferro; NBIA; sinais clínicos; neuroimagem; genética. 
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with neuropathological confirmation of lesions of globus pallidus 
and substantia nigra5. Davidson described in 1954, a case series of 
five patients presenting with progressive parkinsonism, dystonia, 
and spasticity, associated with pyramidal and pallidal lesions, and 
created the term pallidopyramidal degeneration (PPD)6. However, 
this disease was worldwide known as Hallervorden-Spatz syn-
drome (HSS)3. Julius Hallervorden and Hugo Spatz were German 
physicians, who performed several neuropathological studies on 
brain specimens of mental retardation persons, executed during 
the Third Reich euthanasia program (Aktion–T-4)1,2,3. After confir-
mation of Hallervorden and Spatz’s involvement in the euthana-
sia program of the Nazi regime in Germany, and the recent neu-
roimaging and genetic discoveries, this syndrome was renamed 
NBIA1,2. In 2010, Horstink et al. suggested that PPD was a misno-
mer and conclude that the existence of PPD as a distinct noso-
logical entity is doubtful7. In 2013, Kara et al. argued that the use 
of the term NBIA is not ideal and suggested the term pallidopyra-
midal syndromes (PPS), however NBIA is the most known world-
wide term2. To date ten forms of NBIA has been described, eight 
with autosomal recessive inheritance, one autosomal dominant 
form, and one with X-linked dominant inheritance1,2. The most 
common forms are pantothenase kinase-associated neurodegen-
eration (PKAN) (30-50% of NBIA cases), due to mutations in the 
PANK2 gene, followed by phospholipase A2 associated neurode-
generation (PLAN) due to PLA2G6 gene mutations, mitochon-
drial membrane protein-associated neurodegeneration (MPAN) 
due to c19orf12 mutations,  and beta-propeller protein-associated 
neurodegeneration (BPAN) causing SENDA syndrome (static 
encephalopathy of childhood with neurodegeneration in adult-
hood) (gene WDR45, chromosome Xp11.23). Probably most of 
the case published in the literature as HSS were PKAN1. Other 
less common forms are fatty acid hydroxylase-associated neuro-
degeneration (FAHN), coenzyme A synthase protein-associated 
neurodegeneration (CoPAN), Kufor-Rakeb syndrome (PARK9), 
Woodhouse-Sakati syndrome, neuroferritinopathy and acerulo-
plasminemia1,2. The forms of NBIA described to date and the re-
spective gene mutations are listed in Table 1. 
Pantothenase kinase-associated neurodegeneration 
(PKAN)
PKAN is an autosomal recessive disorder characterized 
by mutations in the gene encoding a mitochondrial panto-
thenate kinase (PANK2) at locus 20p13-p12.38. It is the most 
common disorder of the NBIA group9,10,11. The classic clini-
cal presentation of PKAN is characterized by early-onset 
(mean age is 14 years - range from 1 to 28y) and rapidly pro-
gressive course. The affected child presents gait impairment 
and movement disorders (particularly dystonia and par-
kinsonism). Spasticity and brisk tendon reflexes are com-
mon. Cognition is frequently impaired1,12,13,14. Retinitis pig-
mentosa may occur, associated or not with acanthocytes 
in blood cells15,16. The majority of individuals (85%) become 
wheelchairbound within 15 years after the beginning of 
symptoms13,14. Speech and swallowing are affected with dis-
ease progression. Death is usually secondary to respiratory 
infections, cardiorespiratory complications, malnutrition 
state and, rarely, status dystonicus. Atypical phenotypes with 
slowly progressive course have a late onset. Neuropsychiatric 
symptoms are common and may be early signs. They include 
mood lability, impulsivity, non-specific behavioral changes, 
and obsessive-compulsive features 1,14.
Brain magnetic resonance imaging (MRI) plays an im-
portant role in the investigation of PKAN since it shows the 
‘eye-of- the-tiger’ sign, defined as a medial area of hyperintense 
signal within hypointense signal in globus pallidus bilaterally and 
best demonstrated on T2WI and SWI (Figure 1). Hypointense 
signal may also be observed in the substantia nigra15. 
There is no current specific therapy to stop disease progres-
sion. Treatment is supportive and intend to relief associated 
symptoms1,13,14. Dystonia and spasticity are usually managed 
with anticholinergic drugs, benzodiazepines, botulinum toxin, 
oral baclofen and intrathecal baclofen in severe cases. The role 
of the brain iron accumulation in the pathophysiology of the 
disease remains under discussion, and iron chelation therapy 
has been investigated as a disease modifying approach1,14,17.
Phospholipase A2 associated neurodegeneration 
(PLAN)
PLAN is an autosomal recessive form of NBIA. The dis-
ease is caused by failure in the ubiquitously expressed 
PLA2G6 gene, which maps to chromosome 22q13.110,18. This 
gene encodes phospholipase A2 group VI, which may dis-
rupt membrane homeostasis, involved in free fatty acids and 
lysophospholipids synthesis, resulting in neurodegenera-
tion, atrophy, brain iron accumulation, gliosis and degener-
ation of the optic pathways9,19. The majority of PLAN cases 
have early-onset of symptoms, with beginning in childhood. 
PLA2G6-associated diseases have variable syndromes and 
may include: classic infantile neuroaxonal dystrophy (INAD), 
atypical neuroaxonal dystrophy (aNAD) of childhood-onset 
and PLA2G6-related dystonia-parkinsonism with late onset 
in adulthood (PARK14)1,9,13. 
Table 1. Forms of NBIA described to date and the respective 
gene mutations.
NBIA subtype Gene mutation
PKAN PANK2
PLAN PLA2G6
Neuroferritinopathy FTL1
Aceruloplasminemia Ceruloplasmin
BPAN WDR45
Kufor-Rakeb syndrome ATP13A2 (PARK9)
MPAN C19orf12
FAHN FA2H
CoPAN CoASY
Woodhouse-Sakati syndrome C2orf37
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INAD is characterized by early-onset mental developmen-
tal delay, ataxia with cerebellar atrophy, neuropathy and optic 
atrophy. Patients usually have hypotonia, kyphoscoliosis and 
limb contractures. The symptoms usually occurs before 2 years 
old and the progression of the disease is rapid leading to death 
in the first decade9,20. An estimated 50% of patients have abnor-
mal iron accumulation in brain MRI, evolving globus pallidus, 
dentate nuclei and substantia nigra (Figure 2)10. Optic pathway 
atrophy is a relevant clue for the disease9. 
aNAD was previously described as Karak syndrome. This 
disease is less aggressive than classic INAD. The typical clinical 
presentation of aNAD include early-onset (older than INAD) 
ataxia and dysarthria, hypotonia, areflexia, dystonia and cog-
nitive impairment1,20. Children with aNAD may develop optic 
atrophy19. Brain MRI usually have similar features observed in 
INAD: abnormal iron accumulation in globus pallidus, dentate 
nuclei and substantia nigra, and cerebellar atrophy20. 
Adult-onset PLAN with dystonia and parkinsonism, 
described as PARK14, has onset in young adulthood. Clinical 
features include parkinsonism-dystonia syndrome with vari-
able response to dopaminergic medications and neuropsy-
chiatric symptoms9. Brain MRI may be normal or may dis-
close iron accumulation in globus pallidus, substantia nigra 
and striatum21. 
There is no specific treatment for PLAN. Symptomatic treat-
ment for spasticity, dystonia and parkinsonism should be tried1. 
A levodopa course for parkinsonism may improve symptoms13.
Neuroferritinopathy
Neuroferritinopathy is a rare autosomal dominant NBIA 
of adult-onset related to a mutation in the ferritin light chain 
gene FTL1, on chromosome 19q13.319. The onset of symptoms 
is predominantly described in young adulthood or middle 
age1. The clinical manifestation includes psychiatric symptoms 
(psychosis, anxiety and depression), frontal lobe dysfunction, 
dystonia, choreoathetosis, rigidity and spasticity. Other ab-
normalities described in patients with neuroferritinopathy in-
clude lingual dyskinesia, blepharospasm, cerebellar symptoms, 
Figure 1. Brain MRI of a patient with pantothenase kinase-associated neurodegeneration (PKAN). Axial FLAIR- (A) and 
GRE T2-weighted (B) MRI discloses ‘eye-of- the-tiger’ sign, defined as a medial area of hyperintense signal within an hypointense 
signal in globus pallidus bilaterally.
A b
Figure 2. Patient with phospholipase A2 associated neurodegeneration (PLAN) due to PLA2G6 mutations. Brain MRI shows 
marked hypointense signal with iron accumulation in globus pallidus. 
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parkinsonism and palatal tremor10,22. Blood tests show low lev-
els of serum ferritin, typically ≤20 μg/dl, which may reinforce 
the diagnosis22. Brain MRI findings include iron accumulation 
in globus pallidus, caudate, substantia nigra, red nuclei and 
putamen. In late stages of the disease cystic necrosis in basal 
ganglia and globus pallidus may occur22-24. Pathological stud-
ies have demonstrated ubiquitin and tau positive neuroaxonal 
spheroids and neurofilaments, and ferritin-positive inclusions 
in putamen and cerebellum23. Treatment is symptomatic and 
supportive, and dystonia may benefit with botulinum toxin. 
No curative treatments are available22,24.
Aceruloplasminemia
Aceruloplasminemia is an autosomal recessive diseased 
caused by mutation in the ceruloplasmin gene. Ceruloplasmin 
is a copper-bound ferroxidase essential to normal iron metab-
olism, including cell iron efflux and oxidation of ferrous iron 
to ferric iron25. When ceruloplasmin activity is severely de-
creased, iron overload occurs and tissue iron deposition and 
degeneration follows. Iron accumulates primarily in the brain, 
retina and pancreas, giving rise to the classical presentation of 
the disease, a triad consisting of neurological symptoms, reti-
nal degeneration and diabetes mellitus. The prevalence of ac-
eruloplasminemia is higher in Japan26.
Symptoms onset in aceruloplasminemia usually occur in the 
fourth decade. Typically, the first manifestation of the disease is 
diabetes mellitus accompanied by microcytic anemia with low 
serum iron, elevated ferritin and hepatic iron deposition with-
out fibrosis or cirrhosis27. Retinal macular degeneration is usual-
ly asymptomatic28,29. Neurological symptoms develop later in the 
disease, around the sixth decade of life. Movement disorders are 
the most common neurological features in aceruloplasminemia 
and include ataxia, cranio-facial dyskinesias (torticollis, blepha-
rospasm, facial grimacing and tongue dystonia), parkinsonism 
and dysarthria30,31. Dementia and other neuropsychiatric symp-
toms are frequent in aceruloplasminemia30,32.
Diagnosis of aceruloplasminemia is based on the absence 
or very low serum ceruloplasmin. Brain MRI usually disclos-
es severe iron accumulation in caudate, pallidus, putamen, 
dentate nuclei, red nuclei, substantial nigra, thalamus, infe-
rior and superior colliculi and cortex (Figure 3). This wide-
spread pattern of involvement helps distinguish aceruloplas-
minemia from other NBIA, in which iron deposition is either 
more limited (e.g. confined to the pallidus) or associated 
with other features (e.g. cavitation, cerebellar atrophy or thin 
corpus callosum)30,33. White matter T2 hyperintensities can 
also occur34. Heterozygous cases can present with an incom-
plete clinical picture, generating further diagnostic difficul-
ties32,35,36. Genetic testing confirms the diagnosis. 
A number of iron chelating agents have been tried with 
mixed results and data on efficacy is scarce37. Deferasirox re-
duces hepatic but not brain iron overload. Sporadic reports 
have demonstrated that deferasirox and deferiprone may de-
lay neurological symptoms36,38,39. 
beta-propeller protein-associated 
neurodegeneration (bPAN)
BPAN is a X-linked dominant form of NBIA caused by mu-
tations in WDR45 gene, a β-propeller scaffolding protein, as-
sociated with disruption of autophagosome maturation, ac-
cumulation of aberrant autophagic structures and damaged 
cellular components40,41.
Clinically, BPAN is characterized by two phases of dis-
ease: an early neurological disorder with rapid progression 
and a static encephalopathy of childhood. The early on-
set phenotype includes neurological symptoms similar to 
Rett-like syndrome: epilepsy, sleep disorders and global de-
velopmental delay, followed by a rapid progressive onset of 
parkinsonism, dystonia, and dementia14,42. The second form 
is a static encephalopathy of childhood with neurodegenera-
tion in adulthood (SENDA syndrome), which typically pres-
ents with hyperintense signal of the substantia nigra with a 
central band of hypointense signal in brain MRI (Figure 4)43. 
Figure 3. Brain MRI of a patient with aceruloplasminemia MRI discloses global and severe iron accumulation in caudate, pallidus, 
thalamus, putamen (A), red nuclei, substantial nigra (B) and dentate nuclei (C). 
A b C
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Neuropathological studies have disclosed large axonal spher-
oids, siderophages, reactive astrocytes, severe neuronal loss 
and abundant tau-positive neurofibrillary tangles, suggesting 
the occurrence of a tauopathy40,43. 
Kufor-rakeb syndrome - PArK 9
The mutation of the gene ATP13A2 (PARK9) results in a rare 
autosomal recessive form of juvenile parkinsonism, previously 
known as Kufor-Rakeb syndrome44. The first cases described 
presented early parkinsonism, pyramidal signs, upgaze pal-
sy and mental retardation45. However, it is recognized that the 
wide-ranging abnormalities in the gene leads to loss of function 
mutations, which impact the pathophysiological function of 
ATP13A2 protein resulting in considerable clinical heterogene-
ity46. Moreover, the mutations in heterozygous state have been 
found in parkinsonian patients suggesting that heterozygous 
carriers may increase risk for development of the disease45. 
The onset of Kufor-Rakeb syndrome is mostly before the 
age of 20, with variable disease progression. The clinical man-
ifestations comprise levodopa-responsive parkinsonism, dys-
tonia, pyramidal signs, facial-finger mini-myoclonus, supra-
nuclear gaze palsy and cognitive impairment47. Brain MRI 
usually shows global atrophy. The disease is included in NBIA 
group since T2* weighted sequence discloses iron accumula-
tion in basal ganglia in some patients48.
mitochondrial membrane protein-associated 
neurodegeneration (mPAN)
MPAN is an autosomal recessive disease caused by mu-
tations in C19orf12 gene. Pathological studies have demon-
strated increased iron accumulation in the globus pallidus 
and substantia nigra, gliosis, neuronal loss, and eosinophilic 
spheroidal structures in the globus pallidus. The characteris-
tic peripheral axonal spheroids of PLAN may be seen in some 
patients. MPAN is considered a synucleinopathy, with Lewy 
bodies and Lewy neurites in basal ganglia and neocortex19,49.
The disease may manifest from the first decade of life 
(3-16 years) to adulthood (until 30 years). The most common 
features are early lower limb spasticity with extensor plantar 
response, dysarthria, dystonia (involving hands and feet), optic 
atrophy, neuropsychiatric abnormalities and cognitive decline. 
The presentation in adults is more variable, with prominent 
neuropsychiatric symptoms, parkinsonism and gait disorders. 
Others clinical findings that support the diagnosis of MPAN 
are dysphagia, axonal motor neuropathy and bladder and/or 
Figure 4. Brain MRI of a patient with beta-propeller protein-associated neurodegeneration (BPAN) or SENDA. There is a marked 
bilateral hypointense signal in substantia nigra observed in axial and coronal FLAIR (A and B), axial T2 (C) and axial SWI (D) sequences. 
A b
C D
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bowel dysfunction. The disease progression is slow and the 
lifespan is long in most of the cases19,49.
The diagnosis of MPAN is made by detection of biallelic 
pathogenic variants in C19orf12 gene. Brain MRI shows iron 
accumulation in substantia nigra and globus pallidus on T2* 
and GRE sequences, normally without the eye of the tiger 
sign, which is typically found in PKAN. Cortical and cerebel-
lar atrophy may be seen in advanced disease19,49,50. Similar to 
others NBIA, there is no curative treatment and the manage-
ment of patients relies on rehabilitation and symptomatic 
medications: anti-spastic agents, anticholinergics, dopami-
nergic agents and botulinum toxin.
Fatty acid hydroxylase- associated 
neurodegeneration (FAHN)
FA2H mutations were previously known to cause leukodys-
trophy and a form of hereditary spastic paraplegia (HSP), which 
was classified as SPG3551,52,53. FA2H produces 2-hydroxylated 
fatty acids for incorporation into 2-hydroxydihydroceramide 
and 2-hydroxyceramide. These ceramide species serve as 
precursors for the synthesis of galactosylceramides and sul-
fatides, essential lipid components of normal myelin54,55. 
Phenotypically, affected patients demonstrated features simi-
lar to those observed in INAD55. The clinical phenotype is char-
acterized by childhood-onset spastic paraplegia, ataxia and 
dystonia. There are prominent ophthalmologic features such 
as acquired strabismus, nystagmus and optic atrophy. Intellect 
is usually spared in FAHN patients. Seizures may be present51.
Brain MRI in FAHN usually shows bilateral globus pallidus 
T2 hypointense signal, characterizing iron accumulation, pon-
tocerebellar atrophy and cortical atrophy (Figure 5). Confluent 
periventricular T2 white matter hyperintense signal were also 
observed along with thinning of the corpus callosum51,55. It is 
a matter of discussion if FAHN should be included in one or 
more of the 3 following groups: NBIA, HSP or leukodystrophy.
CoA synthase protein associated neurodegeneration 
(CoPAN)
Coenzyme A synthesis (CoASY) is a cofactor in all living 
organisms and is involved in several enzymatic reactions. 
Patients with CoASY mutations present a clinical picture 
similar to those with PKAN. CoPAN phenotype is charac-
terized by early-onset spastic-dystonic paraparesis with a 
later appearance of parkinsonian features, cognitive im-
pairment and pronounced obsessive-compulsive disorder. 
The disease has a slow progression with loss of ambula-
tion during adolescence and adulthood56. Brain MRI usu-
ally shows bilateral “eye-of-the-tiger” sign. CT scan shows 
bilateral calcifications and corresponding to the central 
spot visible on MRI21.
Woodhouse-sakati syndrome and sCPx deficiency
Woodhouse–Sakati syndrome is a rare autosomal re-
cessive disorder caused by a mutation in the C2orf37 gene, 
manifesting with hypogonadism, deafness, alopecia, diabe-
tes mellitus and progressive dystonia, chorea, dysarthria and 
cognitive impairment. Brain MRI discloses iron accumula-
tion in the substantia nigra and globus pallidus, and white 
matter lesions. However, some patients may have only subtle 
white matter abnormalities57,58.
Finally, sterol carrier protein x (SCPx) deficiency has been 
associated with NBIA in a patient with adult-onset spinocere-
bellar ataxia, slow ocular saccades, and deafness. 3T MRI brain 
revealed abnormal T2 signal and susceptibility-weighted se-
quences suggested increased mineral deposition in the basal 
ganglia. Potentially pathogenic mutations were identified in 
SCP2. SCPx is a peroxisomal enzyme with thiolase activity 
required for the breakdown of branched chain fatty acids and 
the pathogenic effects are likely to be mediated by the accu-
mulation of branch chain fatty acids, as in other peroxisom-
al disorders. Patients with SCP2 mutation may have abnor-
mal fatty-acid acyl-CoA metabolism, which has emerged as a 
common disease mechanism in NBIA. This suggests that the 
brain iron accumulation is secondary to an underlying meta-
bolic defect, questioning the role of iron chelation as a treat-
ment in all forms of NBIA59.
Diagnostic approach to neurodegeneration with 
brain iron accumulation
To diagnose the NBIA subtype is a challenge. Careful 
attention to clinical phenotype and neuroimaging features 
is crucial. Family history in order to determine inheritance 
is relevant since mendelian inheritance forms may direct 
investigation to neuroferritinopathy. Neuroimaging fea-
tures may disclose key findings for different NBIA sub-
types (Table 2). Altogether, clinical features including 
non-neurological manifestation, associated movement 
disorders, age at onset, family history and detailed neuro-
imaging characteristics should guide to the genetic test-
ing investigation (Figure 6). 
Figure 5. Patient with fatty acid hydroxylase-associated 
neurodegeneration (FAHN). Brain MRI shows bilateral globus 
pallidus hypointense signal, characterizing iron accumulation, 
and confluent periventricular white matter hyperintense signal. 
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Table 2. Key imaging findings for different NBIA subtypes.
NBIA subtype Neuroimaging features
PKAN “Eye-of-the-tiger” sign due to bilateral symmetrical rarefaction of central globus pallidi
PLAN Iron accumulation in globus pallidi and substantia nigra; cerebellar atrophy    
Neuroferritinopathy Cystic degeneration of globus pallidi, putamen, caudate, substantia nigra and cerebellar nuclei
Aceruloplasminemia Widespread brain iron deposition
BPAN High T1 signal involving substantia nigra; hypointense signal in the substantia nigra
Kufor-Rakeb syndrome Decreased dopamine transporter binding
MPAN T2 hyperintensity in medial medullary lamina between globus pallidus interna and externa
FAHN Iron accumulation in globus pallidi, white matter abnormalities, corpus callosum atrophy 
CoPAN Bilateral “eye-of-the-tiger” sign; CT scan shows bilateral basal-ganglia calcification
Woodhouse-Sakati syndrome Iron accumulation in globus pallidi and white matter abnormalities
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